Blanket Purchase Agreement 36F79724D0159-36E79724A0029
Award Date
8/22/24
Last Date to Order
8/21/25
Federal Agency
National Acquisition Center
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
Actelion Pharmaceuticals US, Inc., a large for-profit pharmaceutical manufacturer, holds multiple Indefinite Delivery Vehicles (IDVs) with the U.S. Department of Veterans Affairs (VA) to provide specialized drug therapies, primarily for the treatment of pulmonary arterial hypertension. These include a $219,108,390 Federal Supply Schedule (FSS-61-IB) contract and two Blanket Purchase Agreements (BPAs) valued at $118.5 million and $83.5 million. The IDVs allow federal agencies, such as the VA...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a component of the Department of Veterans Affairs (VA), to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The BPA, valued at $83.5 million, is for a one-year period from May 2024 to May 2025. The BPA covers the procurement of specialized medications used to treat pulmonary arterial hypertension, including Tracleer, Zavesca, Ventavis, Veletri, Opsumit, Uptravi, and...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to United Therapeutics Corporation. The BPA utilizes the Pharmaceuticals and Drugs GSA Schedule to provide Orentiram, Remodulin, Tyvaso, and Unituxin for an estimated $60 million over a base year and four option years. The BPA aims to procure pharmaceutical products for treatment of pulmonary arterial hypertension and neuroblastoma. Orentiram, Remodulin, and Tyvaso are medications...
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The single-award BPA (Contract #36E79724A0005) has a ceiling value of $5,500,000 and is effective from January 18, 2024 to September 19, 2024. It was awarded without the use of a set-aside and enables the...
Actelion Pharmaceuticals US, Inc., a for-profit manufacturer of specialized pharmaceutical products, holds a $105 million, five-year Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs with the General Services Administration. This IDV allows federal agencies such as the Department of Veterans Affairs (VA) and Bureau of Prisons to procure Actelion's critical drug therapies at pre-negotiated prices. Actelion also holds two Blanket Purchase Agreements (BPAs) established...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs National Acquisition Center to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $3.1 million single-award contract establishes an Indefinite Delivery Vehicle (IDV) for the procurement of orexin inhibitors, a class of sleep-regulating medications, over a one-year base period with four option years. This BPA aims to ensure the availability of...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used. The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026. The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian federal agency, to Merz Pharmaceuticals, LLC, a for-profit foreign-owned organization. The BPA is established under the GSA Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs, with a ceiling value of $12,057,300.00 and a period of performance running through March 12, 2026. The purpose of this BPA is to provide the agency with the pharmaceutical products Ampyra and Inbrijia. No...